NCCN Receives $1 Million Grant From Genentech

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

PHILADELPHIA--The NCCN (National Comprehensive Cancer Network) has received a $1 million unrestricted grant from Genentech, Inc. The grant, provided over a 2-year period, will be used to support the development and expansion of the NCCN Oncology Outcomes Database with emphasis on breast cancer and non-Hodgkin’s lymphoma.

PHILADELPHIA--The NCCN (National Comprehensive Cancer Network) has received a $1 million unrestricted grant from Genentech, Inc. The grant, provided over a 2-year period, will be used to support the development and expansion of the NCCN Oncology Outcomes Database with emphasis on breast cancer and non-Hodgkin’s lymphoma.

The NCCN, established in 1995, is a coalition of 17 leading US cancer centers. To date, the network has developed Oncology Practice Guidelines, which are steadily becoming the standard for clinical and coverage policy in cancer care. To date, NCCN guidelines are available for 93% of all cancers.

The NCCN Oncology Outcomes Database was launched recently in an effort to provide patients, physicians, and payers with a constant flow of data and information to facilitate optimal decision-making in the treatment of all cancers.

"This agreement with Genentech affirms the critical importance of the NCCN’s Oncology Outcomes Database, as well as NCCN’s commitment to the highest quality of cancer care through excellence in research and the collection and analysis of outcomes data," said

NCCN chief executive officer William T. McGivney, PhD, commented, "NCCN implementation of practice guidelines through performance measurement establishes the model for continuous quality improvement in cancer care."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
3 experts in this video
Related Content